IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

Alhemo (concizumab-mtci) injection

Brand: Alhemo. API: concizumab-mtci is used to treat hemophilia A and hemophilia B.

Alhemo (concizumab-mtci) is a prescription subcutaneous (under the skin) injection used for routine daily prophylaxis (prevention) to stop or reduce the frequency of bleeding episodes

Brand Name: Alhemo – On Request
Generic Name: concizumab-mtci
Strength: Injection:
 60 mg/1.5 mL (40 mg/mL) in a single-patient-use prefilled pen
 150 mg/1.5 mL (100 mg/mL) in a single-patient-use prefilled pen
 300 mg/3 mL (100 mg/mL) in a single-patient-use prefilled pen
Manufacturer: Novo Nordisk Inc.
Approved By: EMA, USFDA
Get access to medicines: In India
Price: On Request

See full prescribing information for Alhemo: Patient Information

Get access Alhemo to treat hemophilia A and hemophilia B on a Named Patient Import Basis.

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Alhemo (concizumab-mtci) for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).

For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 |  Mr. Neeraj: +91 9811 747 774.

Contact Info

CORPORATE OFFICE:

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:

info@indianpharmanetwork.co.in

    Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. It is an anti-tissue factor pathway inhibitor.
    The most common adverse reactions include injection site reactions and hives (urticaria). Concizumab can cause thromboembolic events, hypersensitivity, and increased laboratory values of fibrin D dimer and prothrombin fragment 1+2.

    Alhemo (concizumab-mtci) injection, for subcutaneous use Initial U.S. Approval: 2024

    Is Alhemo (concizumab-mtci) available in India?

    Alhemo (concizumab-mtci) may be accessed in India through a named-patient import process with a valid doctor’s prescription, and Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing and delivery of specialty medicines subject to regulatory approvals.

    How to get Alhemo Injection delivered in India?

    Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations. Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.

    IPN having representation in Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.

    Who can help source Alhemo Injection in India legally?

    Named-patient import facilitator contact details
    Company Name: Indian Pharma Network (IPN)
    Address: 60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
    For sourcing and import coordination of specialty medicines, contact:
    Mr. Tarun: +91 9891 296 838
    Mr. Neeraj: +91 9811 747 774
    Email: info@indianpharmanetwork.co.in

    Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.

    Note:
    We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India.

    Indian Pharma Network (IPN), New Delhi. India

    Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
    Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
    Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

    Indian Pharma Network
    60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

    Mobile / WhatsApp / Phone
    M: +91 9811747774, 9891296838.
    P: +91-11-26532129 / 26536398